A Phase III, Equivalence Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of 100 microg Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Ovarian Stimulation Using Daily Recombinant FSH as Reference.

Trial Profile

A Phase III, Equivalence Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of 100 microg Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Ovarian Stimulation Using Daily Recombinant FSH as Reference.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Corifollitropin alfa; Follitropin beta
  • Indications Female infertility
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ENSURE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 May 2015 Last checked against ClinicalTrials.gov record (extension study NCT00702546).
    • 12 May 2015 Last checked against ClinicalTrials.gov record (extension study NCT00702546).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top